Navigation Links
Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP
Date:7/24/2014

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all. This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame.

Lpath has enrolled 26 patients in the study. ASONEP has a favorable safety profile thus far, with no serious adverse events (SAEs) deemed to be drug-related.

The first 17 patients were initiated at a dose of 15 mg/kg. Of these "lower-dose" patients:  7 had progressive disease at or before the end of four months; 8 were progression-free at the four-month mark (with 1 of these patients deemed a partial responder per Response Evaluation Criteria in Solid Tumors (RECIST) criteria and with 3 of these patients experiencing reduced tumor volume, but not enough to be categorized as a RECIST-based partial responder); and 2 exited the study due to SAEs unrelated to the drug prior to the four-month mark (and are not considered evaluable). Notably, of the 8 patients that were stable or better as of month four, 2 are now in their fifteenth month on the study, 1 is in month thirteen, and 1 is in month ten. An additional patient was stable through month seven, but then missed six treatments during a vacation, and shortly thereafter progressed.

The next 9 patients were initiated at a dose of 24 mg/kg. Of these higher-dose patients: 4 had progressive disease at or before
'/>"/>

SOURCE Lpath
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lpath Withdraws From Pfizers Process to Assign iSONEP Rights
2. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
3. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
4. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
5. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
6. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
7. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
8. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
9. Luminex Corporation Reports First Quarter 2012 Results
10. Hospira Reports First-Quarter 2012 Results
11. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "Inhaled Drug Delivery (London, UK - ... This Inhaled Drug Delivery meeting will cover industry ... and much more. The Co-Chairmen are Dr Steven ... , Senior Director, Mylan. Companies participating ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "An Introduction to ... - November 2-3, 2015)" conference to their ... a comprehensive introduction to the regulations and requirements ... will be highly interactive, using real life examples ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... (Nasdaq:,CRYO), a medical device company focused on the treatment ... its pivotal,clinical study for the treatment of atrial fibrillation. ... said, "This is a,major milestone for CryoCor, being the ... for the use of ablation for the treatment of,atrial ...
... Novogen Limited,s subsidiary, Marshall Edwards Inc. (Nasdaq: MSHL ), has ... made the following ... Marshall Edwards, Inc. (Nasdaq: MSHL ) today announced enrolment of ... of,phenoxodiol in women with advanced ovarian cancer resistant or refractory,to platinum-based ...
Cached Medicine Technology:CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 2First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 3First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 4First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 5First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial 6
(Date:9/3/2015)... ... September 03, 2015 , ... Local filmmakers and now co-hosts of ... Habernig from Path 11 Productions have had great success in launching their Path11 Podcast ... Hay House authors, Teal Swan who is the well known Spiritual Catalyst and Linda ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... Bob Anders and Kelley Chapman will be joining the company’s executive leadership team ... Anders has over 30 years’ experience in healthcare product and project management. He ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... robust distribution channels and efficient customer and technical support services to promote LodonalTM ... approved 90-day Bridging trial evaluating the efficacy and safety of the product. , ...
(Date:9/2/2015)... ... 03, 2015 , ... The Aspen Clinic (TAC), located in Basalt, ... kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, ... mind-body approach to fitness - we are much more than a gym. Our ...
(Date:9/2/2015)... ... ... One can hardly argue against the fact that more and more people ... These devices are being used as GPS, to make purchases, and yes, even to ... positive singles can now join the prestigious social ranks of e-dating. , Recently, ...
Breaking Medicine News(10 mins):Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2
... boy who tested HIV positive was tied to his bedpost at ... Meerut since April after committing a robbery. He tested HIV positive ... the Medical College, which proved to be hopelessly inadequate to deal ... ten days ago when a blood test confirmed he was HIV ...
... form of viral fever spread by mosquitoes has been ... and Family Welfare Panabaka Lakshmi said Friday.// ,"High ... 18 districts of Andhra Pradesh, 27 district of Karnataka, ... four districts of Madhya Pradesh," Lakshmi told the Rajya ...
... to making use of an actor in its advertising campaign ... shows a heavily made-up woman displaying rotten teeth, ... that smoking caused her mouth cancer. "If it didn't, I ... ,Todd Harper, Quit executive director, said the agency had decided ...
... by experts in respiratory diseases to warn patients that ... used to treat the more severe forms of asthma. ... who penned an editorial in the Journal of the ... include Serevent, salmeterol and formoterol, should always be used ...
... air fresheners and toilet bowl cleaners, contain a ... to the lungs.// ,Stephanie London and ... Health Sciences (NIEHS) examined 953 adults exposed to ... one compound called 1,4 dichlorobenzene (1,4 DCB) may ...
... within a week this month due to heavy downpour that ... officials said. ,The onset of monsoon has always ... the Sherap Gatsel school, nestled in the foot of a ... School. ,"As of now all the students have ...
Cached Medicine News:
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
... flow while minimizing the pain ... the safety-engineered BD Microtainer Genie ... Lancet offers a full range ... capillary blood collection and protects ...
For patient-friendly and safe capillary blood collection...
... a widely used screening test for determining ... oriented Dispette branded system is considered the ... stamp. No other system meets defined NCCLS/ICSH ... care. Specialized systems are also available for ...
Medicine Products: